GlassScriptPhysician profile
Bachar Y Malek
NPI 1043282627
$2,433.42
in general payments reported to CMS, 2019-2025
34 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $230 · 2021: $621 · 2022: $755 · 2023: $247 · 2024: $113 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.38 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $287.24 | 2020-2022 | |
| Merz North America, INC. | $228.23 | 2022-2024 | |
| Lilly USA, LLC | $147.59 | 2019-2022 | |
| Pfizer INC. | $140.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $117.34 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $106.71 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $104.34 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $81.76 | 2021 | |
| Indivior INC. | $79.08 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $69.26 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.07 | 2022 | |
| Merck Sharp & Dohme LLC | $64.57 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $55.27 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $54.34 | 2024 | Abilify Maintena, Abilify Asimtufii |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $45.94 | 2021 | |
| Abbott Laboratories | $37.63 | 2021-2022 | |
| Alkermes, INC. | $33.20 | 2022-2025 | Aristada, Lybalvi |
| Hologic Sales and Service, LLC | $32.42 | 2020-2022 | |
| Neuronetics, INC. | $30.10 | 2022 | |
| Horizon Therapeutics Plc | $27.54 | 2022 | |
| Sanofi-Aventis U.S. LLC | $26.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.44 | 2021 | |
| Itamar Medical INC | $19.48 | 2025 | Watchpatone |
| Axsome Therapeutics, INC. | $19.37 | 2025 | Auvelity |
| Genentech USA, INC. | $16.49 | 2019 | |
| Corium, LLC | $16.34 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.51 | 2019 | |
| Antares Pharma, INC. | $14.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.66 | 2020 | |
| Lundbeck LLC | $14.18 | 2022 | |
| Covis Pharma Gmbh | $13.30 | 2022 | |
| Astellas Pharma US INC | $12.26 | 2019 | |
| Stimwave Technologies Incorporated | $2.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bachar Malek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.